Asymchem (Stock Code: 002821.SZ/6821.HK) is a global CDMO leader with 25 years of experience, providing one-stop solutions across the pharmaceutical value chain. Specializing in small molecules, chemical macromolecules, biologics, synthetic biology, and more, Asymchem operates R&D and manufacturing facilities in China, the U.S., and the U.K., supported by a team of 9,000 professionals. Trusted by global pharma and biotech leaders, Asymchem delivers cGMP-compliant, cost-effective services to accelerate drug development and address diverse client needs. The Center of Synthetic Biology Technology (CSBT) at Asymchem leverages two core technology platforms: enzyme engineering and cell engineering—to establish end-to-end capabilities from laboratory R&D to industrial-scale production. CSBT’s technology offerings extend across pharmaceuticals, nutraceuticals, and other fine chemical sectors. Committed to providing partners with efficient and sustainable biosynthetic solutions, empowering innovation in the green bioeconomy.